Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Leite, AR (Author) Other; Angelico Goncalves, A (Author) Other; Vasques Novoa, F (Author) FMUP; Borges Canha, M (Author) FMUP; Leite-Moreira AF (Author) FMUP; Neves, JS (Author) FMUP; Ferreira, JP (Author) FMUP

Journal

Title: Diabetes, Obesity and Metabolism

Vol. 24

Pages: 1676-1680

ISSN: 1462-8902

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 9 Citations

Scopus - 9 Citations

Other information

Authenticus ID: P-00W-BSQ

DOI: 10.1111/dom.14707

Abstract (EN): Our aim was to study the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) on the risk of any cardiovascular event in adults with overweight or obesity and without diabetes. We conducted a random-effects meta-analysis of placebo-controlled randomized controlled trials. Nine trials were eligible and, in total, 11 430 patients were included, of which 7702 (67%) were submitted to treatment with GLP-1 RA. During follow-up, 673 participants receiving GLP-1 RA treatment (8.7%) and 416 participants receiving placebo (11.2%) had a cardiovascular event. Treatment with GLP-1 RA versus placebo resulted in a reduction in the risk of any cardiovascular event (RR = 0.81, CI 0.70-0.92; p = .001). In overweight or obese adults without diabetes, treatment with GLP-1 RA reduced the risk of cardiovascular events. Our findings support the use of GLP-1 RA for reducing the cardiovascular risk of these patients.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 5